Assistant Professor of Medicine, Brigham and Women's Hospital
Internal Medicine
Dr. Aaron S. Kesselheim, MD
|
|
Give Review
Aaron Kesselheim is an expert in the field of Internal Medicine. He went to medical school at Perelman School of Medicine at the University of Pennsylvania. Doctor Aaron S. Kesselheim, MD is a published MD. He has 104 publications published. The most current publication "Inaccurate Reporting of Insulin Reimbursement-Reply." He is registered with Medicare and accepts Medicare payments.
Publications
- Evolution of insulin patents and market exclusivities in the USA.
- Two decades of new drug development for central nervous system disorders.
- Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.
- Comparative effectiveness of generic versus brand-name antiepileptic medications.
- Experience With the Priority Review Voucher Program for Drug Development.
- Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
- Paying physicians to prescribe generic drugs and follow-on biologics in the United States.
- Variations in Time of Market Exclusivity Among Top-Selling Prescription Drugs in the United States.
- Paying for innovation: Reimbursement incentives for antibiotics.
- Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.
- Medical device postapproval safety monitoring: where does the United States stand?
- FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.
- Development and Use of New Therapeutics for Rare Diseases: Views from Patients, Caregivers, and Advocates.
- Association of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross...
- A cross-national comparison of 17 countries' insulin glargine drug labels.
- Electronic medication packaging devices and medication adherence: a systematic review.
- Chemotherapy Parity Laws: A Remedy for High Drug Costs?
- Introduction to a Supplement on Innovative Approaches to Studying Health Outcomes in Rare Diseases.
- Association of Marketing Interactions With Medical Trainees' Knowledge About Evidence-Based Prescribing: Results From a National Survey.
- The Food and Drug Administration's Role in Promoting Consistent Labels for Generic Drugs.
- Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology.
- Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.
- Target small firms for antibiotic innovation.
- A matter of trust: patient barriers to primary medication adherence.
- Postmarketing Trials and Pediatric Device Approvals.
- Underrepresentation of older adults in cancer trials.
- What is the public's right to access medical discoveries based on federally funded research?
- Strategies for postmarketing surveillance of drugs for rare diseases.
- The evolving role of biomarker patents in personalized medicine.
- Clinical and regulatory features of drugs not initially approved by the FDA.
- Same song, different audience: pharmaceutical promotion targeting non-physician health care providers.
- Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980-2009.
- Defining "innovativeness" in drug development: a systematic review.
- Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China.
- Patterns and predictors of generic narrow therapeutic index drug use among older adults.
- Erratum to: Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey.
- Who Is Now Responsible for Discovering and Warning About Adverse Effects of Generic Drugs?
- Balancing access and innovation: India's Supreme Court rules on imatinib.
- The most transformative drugs of the past 25 years: a survey of physicians.
- Distributions of Industry Payments to Massachusetts Physicians.
- Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.
- Drug company gifts to medical students: the hidden curriculum.
- Variations in pill appearance of antiepileptic drugs and the risk of nonadherence.
- FDA regulation of off-label drug promotion under attack.
- Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey.
- Drug labels: a flawed source of data for studying orphan drug approvals.
- Ethical considerations in orphan drug approval and use.
- Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.
- Research ethics. Paying patients for their tissue: the legacy of Henrietta Lacks.
- False claims act prosecution did not deter off-label drug use in the case of neurontin.
- Clinical decision support systems could be modified to reduce 'alert fatigue' while still minimizing the risk of litigation.
- "Pay for Delay" Settlements of Disputes over Pharmaceutical Patents.
- Conflict of interest disclosure in early education of medical students.
- An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.
- Who Owns Federally Funded Research? The Supreme Court and the Bayh-Dole Act.
- Reputation and precedent in the bevacizumab decision.
- The backlash against bioequivalence and the interchangeability of brand-name and generic drugs.
- Why do the same drugs look different? Pills, trade dress, and public health.
- Conflict of interest in oncology publications: A survey of disclosure policies and statements.
- Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
- Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review.
- Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy.
- The consequences of requesting "dispense as written".
- Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.
- Residents: workers or students in the eyes of the law?
- The NIH translational research center might trade public risk for private reward.
- Off-label drug use and promotion: balancing public health goals and commercial speech.
- Improving antibiotic markets for long-term sustainability.
- Adalimumab pricing and market exclusivity for biologics.
- Pharmaceutical marketing and the new social media.
- Using market-exclusivity incentives to promote pharmaceutical innovation.
- Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment.
- Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature.
- Questions about the 10 x '20 Initiative.
- Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
- State generic substitution laws can lower drug outlays under medicaid.
- Managing financial and nonfinancial conflicts of interest in healthcare delivery.
- Incentives for drug development--the curious case of colchicine.
- Gene patenting--is the pendulum swinging back?
- Whistle-blowers' experiences in fraud litigation against pharmaceutical companies.
- Meta-analyses involving cross-over trials: methodological issues.
- The Supreme Court, process patents, and medical innovation.
- Balancing innovation, access, and profits--market exclusivity for biologics.
- Expert review of drug patent applications: improving health in the developing world.
- How Medicare could get better prices on prescription drugs.
- The Supreme Court, preemption, and malpractice liability.
- Using patent data to assess the value of pharmaceutical innovation.
- Professional oversight of physician expert witnesses: an analysis of complaints to the Professional Conduct Committee of the American Association of Neurological Surge...
- Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.
- Drug development for neglected diseases - the trouble with FDA review vouchers.
- Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005.
- Pharmaceutical promotion to physicians and First Amendment rights.
- The international pharmaceutical market as a source of low-cost prescription drugs for U.S. patients.
- Scientific and legal viability of follow-on protein drugs.
- Think globally, prescribe locally: how rational pharmaceutical policy in the U.S. can improve global access to essential medicines.
- Market-based licensing for HPV vaccines in developing countries.
- Role of professional organizations in regulating physician expert witness testimony.
- The variability and quality of medication container labels.
- Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
- Inaccurate Reporting of Insulin Reimbursement-Reply.
- Insulin patents and market exclusivities: unresolved issues - Authors' reply.
- Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies.
- The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
Schools
Perelman School of Medicine University of Pennsylvania
Brigham and Women39s Hospital
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Brigham and Women's Faulkner Hospital -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1063478626 | |
| NPPES Provider LastName | KESSELHEIM | |
| NPPES Provider FirstName | AARON | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 1069.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 1.5 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063478626 |
| Last Name Of The Provider | KESSELHEIM |
| First Name Of The Provider | AARON |
| View All |
Similar Doctors
|
|
Dr. Sung J. Lieu, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander S. Rabin, MD |
|
|
Dr. Brian J. Carney, MD |
|
|
Dr. Daniel M. Horn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Barker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey L. Greenwald, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul B. Yu, MD |
|
|
Dr. Adam V. Meyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven R. Levisohn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kate E. Koplan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Azadeh Nasseh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ali A. Duarte Garcia, MD |
|
|
Dr. Marianne Barry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer K. Hughes, MD |